China Breast Cancer Diagnostics And Therapeutics Market Share 2019 Growth Challenges, Opportunities and Future Trends 2025
China breast cancer diagnostics and therapeutics market are estimated to grow significantly at a CAGR of 10.2% during the forecast period. Increasing the incidence of breast cancer coupled with a growing awareness program towrds breast cancer diagnosis and treatment are the major factors that contributing to the growth of the market. According to the National Central Cancer Registry (NCCR), about 268.6 thousand new cases were estimated in 2015. The breast cancer cases estimated about 189.5 thousand in the urban area and 79 thousand cases in the rural area. Moreover, the mortality by breast cancer was estimated at about 69.5 thousand in the country that further raises the demand for diagnosis and treatment solutions in the country that further propels the market growth.
To Request a Sample of our Report on China
Breast Cancer Diagnostics And Therapeutics Market: https://www.omrglobal.com/request-sample/china-breast-cancer-diagnostics-therapeutics-market
China breast cancer diagnostics and therapeutics market are
segmented on the basis of cancer type, diagnostics, and therapeutics. In cancer
type segment market is further classified into ductal carcinoma in-situ (DCIS),
invasive ductal carcinoma (IDC), triple negative breast cancer (TNBC),
inflammatory breast cancer and others. In diagnostics technology, the segment
market is further classified into mammography, biopsy, position emission
tomography/computed tomography, ultrasound, and others. The therapeutics
technology segment market is further segregated into chemotherapy, hormone
therapy, targeted therapy, and others.
(Get 15% Discount on Buying this Report)
A
full Report of China Breast Cancer Diagnostics And Therapeutics Market is
Available @ https://www.omrglobal.com/industry-reports/china-breast-cancer-diagnostics-therapeutics-market
China Breast Cancer
Diagnostics And Therapeutics Market Segmentation
By Cancer Type
·
Ductal Carcinoma In-Situ (DCIS)
·
Invasive Ductal Carcinoma (IDC)
·
Triple Negative Breast Cancer (TNBC)
·
Inflammatory Breast Cancer
·
Others (Invasive lobular carcinoma)
By Diagnostics
·
Mammography
·
Biopsy
·
PET/CET
·
Ultrasound
·
Others (MRI)
By Therapeutics
·
Chemotherapy
·
Hormone Therapy
·
Targeted Therapy
·
Others (Radiation Therapy, Surgery)
Company Profiles
·
AstraZeneca PLC
·
Bayer AG
·
GlaxoSmithKline PLC
·
Johnson & Johnson Services, Inc.
·
Merck & Co., Inc.
·
Novartis International AG
·
F. Hoffmann-La Roche AG
·
Sanofi S.A.
·
Siemens Healthcare GmbH
·
Sun Pharmaceutical Industries Ltd.
·
Pfizer Inc.
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment